Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Email from Bob - received Friday:

<< Previous

Bullboard Posts

Next >>

Post by Bawkeron Dec 06, 2020 6:19pm

816 Views

Post# 32046863

Email from Bob - received Friday:

 		"Here is a status update re resumption of trading:

 		Kalytera filed all required filings - more than a month ago.
 		 
 		We applied to the British Columbia Securities Commission ("BCSC") and the Ontario Securities Commission ("OSC") to have the CTO revoked - more than a month ago.
 		 
 		Last Friday, the BCSC and OSC finally replied to our applications with only some minor comments .
 		 
 		If the BCSC and OCS to remove the CTO, the TSXV will allow our shares to resume trading.
 		 
 		When the CTO is removed, and the shares resume trading, we will make several announcements regarding our new program developing R-107 as both a prophylactic and as a therapy for COVID-19 infection, as well as other viral infections.